Drugs / Lopinavir/ritonavir
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00887120 Comparator | Apr 2007 → Jan 2009 | HIV infectious disease | The HIV Netherlands Australia Thailand Research Collaboration | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-02-27 | AbbVie | AbbVie Statement on Coronavirus and lopinavir/ritonavir abbvie.com ↗ |
| 2006-08-17 | Vertex Pharmaceuticals Incorporated | Head-to-Head Study Comparing LEXIVA(R) (fosamprenavir calcium) to Kaletra Presented at IAC 2006 and Published in The Lancet vrtx.com ↗ |
| 2006-05-16 | Vertex Pharmaceuticals Incorporated | GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV vrtx.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lopinavir/ritonavir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00887120 ↗ |
| Known as | Kaletra | “Pharmacokinetics and Efficacy of Low- or Standard-dose of Lopinavir/Ritonavir (Kaletra®) in PI-naïve HIV-1 Infected Children” NCT00887120 ↗ |
| Known as | LPV/r | “Dose of Lopinavir/ritonavir (LPV/r)” NCT00887120 ↗ |
| Action | Inhibit | “Lopinavir/ritonavir is a common protease inhibitor (PI) used for second-line regimens in children.” PMID 19729375 ↗ Sep 2009 |
| Route | Oral | “1.5 mL oral q 12 hr” NCT00887120 ↗ |